AI assistant
Vitrolife — Share Issue/Capital Change 2018
May 31, 2018
2989_rns_2018-05-31_10d4173b-37fc-4cff-b158-75784364f410.pdf
Share Issue/Capital Change
Open in viewerOpens in your device viewer
Press release May 31, 2018 Gothenburg
Increase in the number of shares and votes in Vitrolife AB
Due to stock split 5:1, implemented in accordance with the decision of the Annual General Meeting, the number of shares in Vitrolife AB has increased from 21,710,115 to 108,550,575, with an equal number of votes. The share capital remains unchanged SEK 22,144,317.
May 31, 2018 Gothenburg VITROLIFE AB (publ) Thomas Axelsson, CEO
Contact persons:
Thomas Axelsson, CEO, tel: +46 31 721 80 01 Mikael Engblom, CFO, tel: +46 31 721 80 14
___________________________________________________________________________________________________________________________________ Vitrolife is an international medical device Group. Vitrolife develops, produces and markets products for assisted reproduction.
Vitrolife today has approximately 370 employees and the company's products are sold in approximately 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in Australia, Belgium, China, Denmark, France, Germany, Italy, Japan, United Kingdom and USA. The Vitrolife share is listed on NASDAQ Stockholm.
_____________________________________________________________________________________________________
Vitrolife AB (publ), Box 9080, SE-400 92 Gothenburg. Corporate ID number 556354-3452. Tel: +46 31 721 80 00. Fax: +46 31 721 80 99. E-mail: [email protected]. Website: www.vitrolife.com
This information is information that Vitrolife AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 10.00 am CET on May 31, 2018.